副溶血性弧菌-霍乱弧菌混合生物被膜形成过程研究

【目的】研究副溶血性弧菌(Vibrioparahaemolyticus,VP)和霍乱弧菌(Vibriocholera,VC)混合生物被膜的形成过程。【方法】在4、8、12、24、36、48、60、72 h测定单独条件下VP、VC及其混合后生物被膜的形成情况,通过结晶紫染色法、平板菌落计数法、测定胞外多糖、胞外蛋白,通过荧光原位杂交(FISH)观察混合生物被膜形成。【结果】虽然形成的混合生物被膜量介于VC和VP之间,但混合生物被膜在形成过程中,成熟期后生物被膜量的变化较小,对环境的抗性增强。混合生物被膜中拥有更多的活菌,混合生物被膜形成过程中胞外蛋白和胞外多糖的变化体现出其可能在对抵御不适应环境中起重要作用,通过FISH可观察到不同时期生物被膜的变化过程。【结论】VC与VP共同形成生物被膜的过程中,混合生物被膜总量虽然减少,但混合生物被膜中拥有更多的活菌,这可能引起更大的危害。研究混合生物被膜形成过程中被膜的变化,可为有害生物被膜的控制提供基础。     

草酸对黄瓜根中铁还原的促进作用

用黄瓜为材料 ,研究了草酸对植物根切段还原Fe(Ⅲ )EDTA的促进作用。在 2～ 14mmol/L范围内随着草酸浓度的加大 ,其促进作用不断提高 ;在 4h内随着反应时间的推移 ,Fe(Ⅲ )EDTA的还原量成线性上升趋势。进一步用完整根、粗酶提取液和提纯的质膜证明 :促进作用并非草酸本身作为电子供体直接或间接地加速了铁还原反应 ,而是形成的草酸铁螯合态是根中铁还原酶更有效的底物。整体根还原草酸铁的活力和质膜铁还原酶催化草酸铁的效率 (Vmax/Km)都远大于还原柠檬酸铁和Fe (Ⅲ )EDTA的活力和效率     

Epigallocatechin-3-gallate对原代大鼠脂肪细胞脂肪分解及HSL、TGH转录表达的影响

体内能量代谢是维持机体正常生理活动的基础,而脂肪细胞的脂解是能量代谢的核心反应之一,调控脂肪酸从TG库释放,后由血清白蛋白转运至体内各个组织以满足能量需要。如果脂解作用出现障碍,就会影响机体能量的平衡进而引发肥胖和胰岛素抵抗等疾病。表没食子儿茶素没食子酸酯(Epig     

杨盘二孢菌诱导的杨树差异表达基因的功能分析和染色体定位

利用cDNA芯片技术从含有2,952个克隆的杨树芯片中筛选出1,160个受杨盘二孢菌诱导的基因。功能分析表明,该1,160个基因分别属于11个功能类别,除了功能未知基因外,参与新陈代谢、防御反应、信号传导及转录调控的基因最多,这4大类基因约占基因总数的42%。1,160个差异表达基因中有926个基因被定位于19条染色体上,其中被定位于第Ⅱ条染色体上的差异基因最多,共102个(11.0%),其次是第Ⅰ条染色体,共93个(10%),被定位到第ⅩⅦ条染色体上的差异基因最少,仅有11个,基因在染色体上的分布则表现为在部分染色体的末端区域存在大量的聚集,在中间区段则相对较少和排列稀疏,基因的这种分布情况与植物抗病的关系有待进一步研究。     

裂叶苣荬菜的研究

本文对裂叶苣荬菜(Sonchus arvensis L)进行了初步研究。考察了它的植物生态特征和分布环境,预试了化学成分并进行了临床病例观察。为裂叶苣荬菜以其本名作为治疗肝炎的草药入药提供了可靠的依据。     

PLA2R-IgG间接荧光定量免疫层析分析的构建与应用

目的 血清抗磷脂酶A2受体抗体IgG (PLA2R-IgG)水平是诊断和治疗特发性膜性肾病（IMN）的重要依据,而目前国内外常规检测手段主要是酶免法。为提升检测的便捷性,同时满足灵敏、宽量程分析需求,本研究构建了一种新的PLA2R-IgG检测技术。方法 采用包裹铕元素的微球示踪,对反应步骤进行选择,对微球制备液的p H、微球-抗体反应比例和反应时间优化,本文基于间接法构建了PLA2R-IgG的荧光定量免疫层析检测方法,并进行了初步临床评价。结果 本方法的灵敏度达0.7 RU/ml,标准曲线方程为y=0.771x-1.437,相关系数0.995,线性测量范围为0.7～1 500 RU/ml,回收率为86.27%～98.98%,平均批内变异系数为8.13%,交叉反应率均小于0.1%,试剂37℃储存10 d稳定。本方法与市售酶免试剂盒相关性为0.953,阴阳性判断一致,对IMN的检出率为76.9%。结论 采用两步法反应的PLA2R-IgG间接荧光定量免疫层析分析,快速、灵敏、准确,具有临床实用性。     

Preparation and application of freeze-dried platelets

Clinical platelet infusion is primarily used to prevent or stop bleeding, but can also have a role in treating infections or promoting wound healing. The demand for platelets has increased in recent years. However, as platelets can only be stored for short periods, there is a substantial loss due to the products reaching their expiry date. Platelet lyophilization is a particularly valuable and important research field. The purpose of studying the freeze-drying preservation of platelets is to realize the long-term preservation of platelets at room temperature. It is very possible to prepare qualified freeze-dried platelets. However, there are still problems that have not been solved in the process of platelet lyophilization. This review mainly summarizes research progress in the preparation and application of freeze-dried platelets.     

Implication of the hepatokine,fibrinogen-like protein 1 in liver diseases,metabolic disorders and cancer: The need to harness its full potential

Fibrinogen-like protein 1 (FGL1) is a novel hepatokine that forms part of the fibrinogen superfamily. It is predominantly expressed in the liver under normal physiological conditions. When the liver is injured by external factors, such as chemical drugs and radiation, FGL1 acts as a protective factor to promote the growth of regenerated cells. However, elevated hepatic FGL1 under high fat conditions can cause lipid accumulation and inflammation, which in turn trigger the development of non-alcoholic fatty liver disease, diabetes, and obesity. FGL1 is also involved in the regulation of insulin resistance in adipose tissues and skeletal muscles as a means of communication between the liver and other tissues. In addition, the abnormally changed FGL1 levels in the plasma of cancer patients make it a potential predictor of cancer incidence in clinical practice. FGL1 was recently identified as a major functional ligand of the immune inhibitory receptor, lymphocyte-activation gene 3 (LAG3), thus making it a promising target for cancer immunotherapy except for the classical programmed cell death protein 1/programmed cell death ligand 1 (PD-1/PD-L1) axis. Despite the potential of FGL1 as a new cancer biomarker and therapeutic target, there are few related studies and much of what has been reported are superficial and lack depth and particularity. Therefore, elucidating the role and underlying mechanisms of FGL1 could be crucial for the development of promising diagnostic and therapeutic strategies for related diseases. Here, we provide a comprehensive review of the cellular mechanisms and clinical prospects of FGL1 in the prevention and treatment of liver diseases, metabolic disorders and cancer, and proffer suggestions for future studies.